OpenBind is generating foundational structural biology data to power the next era of AI/ML for drug discovery.
OpenBind is an open science initiative accelerating drug discovery by generating massive, high-quality, fit-for-purpose protein-ligand structure and affinity datasets. By combining automated crystallography, microscale chemistry, open-source models, and blind community challenges, OpenBind powers the next generation of machine learning tools for structure-based drug design, freely available to all.
The UK Department for Science, Innovation, and Technology (DSIT) newly established Sovereign AI unit announced an £8 million investment in the OpenBind Consortium to catalyze a transformation in AI for small molecule drug discovery through an accelerated data generation effort centred at the Diamond Light Source.